🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome

Recruitingn/aAges 18 Years - 45 YearsFemaleIRCCS San Raffaele
NCT05786235 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS. To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM). For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Group 1 1. Pregnant patients between the ages of 18 and 45 years. 2. Diagnosis of primary APS, according to international classification criteria. * Group 2 1. Pregnant patients between the ages of 18 and 45 years. 2. Patients with at least one previous full-term pregnancy. 3. No diagnosis of APS, according to international classification criteria. Exclusion Criteria: * Group 1 1. PMA pregnancies. 2. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 3. Previous thrombotic event 4. Chronic renal failure not related to AD 5. Previous history of oncology * Group 2 1. Pregnancy by PMA. 2. Previous history of polyabortion and/or late pregnancy complications. 3. Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology 4. Previous thrombotic event 5. Previous history of oncology
💊

What it tests

  • Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
  • Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
📍

Where

1 site
San Raffaele Hospital
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy